The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation |
Kim, Eunji
(Department of Pharmacy, Seoul National University Bundang Hospital)
Kim, Boram (Department of Pharmacy, Seoul National University Bundang Hospital) Cho, Jungwon (Department of Pharmacy, Seoul National University Bundang Hospital) Lee, Jung Hwa (Department of Pharmacy, Seoul National University Bundang Hospital) Lee, Eunsook (Department of Pharmacy, Seoul National University Bundang Hospital) Yu, Yun Mi (Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei Unversity) Cho, Jai Young (Department of Surgery, Seoul National University College of Medicine & Seoul National University Bundang Hospital) Lee, Euni (College of Pharmacy & Research Institute of Pharmaceutical Science, Seoul National University) Choi, YoungRok (Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital) |
1 | Pichlmayr R, Winkler M, Neuhaus P, et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. Transplant Proc 1997;29:2499-502. DOI |
2 | Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol 2015;7:1355-68. DOI |
3 | Senft JD, Gotthardt DN, Frischbier L, Bruns H, Schemmer P. A retrospective comparison of mycophenolate mofetil with lowexposure cyclosporine versus standard cyclosporine therapy in de novo liver transplant patients. Ann Transplant 2015;20:539-43. DOI |
4 | Taber DJ, Su Z, Fleming JN, et al. Tacrolimus trough concentration variability and disparities in african american kidney transplantation. Transplantation 2017;101:2931-8. DOI |
5 | Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Timedependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014;85:1404-11. DOI |
6 | Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010;25:2757-63. DOI |
7 | Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and metaanalysis. Am J Transplant 2012;12:2797-814. DOI |
8 | Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010;14:968-75. DOI |
9 | Whalen HR, Glen JA, Harkins V, et al. High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime. Transplantation 2017;101:430-6. DOI |
10 | O'Regan JA, Canney M, Connaughton DM, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol 2016;29:269-76. DOI |
11 | Shuker N, Shuker L, van Rosmalen J, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int 2016;29:1158-67. DOI |
12 | Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012;34:680-5. DOI |
13 | Van der Veer MAA, Nangrahary N, Hesselink DA, et al. High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation. Transplantation 2019;103:2329-37. DOI |
14 | Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimusrelated adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000;13:73-8. DOI |
15 | Rayar M, Tron C, Jezequel C, et al. High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poor outcomes. Transplantation 2018;102:e108-14. DOI |
16 | Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. Transplantation 2013;58:262-70. DOI |
17 | Goodall DL, Willicombe M, McLean AG, Taube D. High intrapatient variability of tacrolimus levels and outpatient clinic nonattendance are associated with inferior outcomes in renal transplant patients. Transplant Direct 2017;3:e192. DOI |
18 | Agarwala S, Culligan E, Jain A, et al. Evaluation of renal function in transplant patients on tacrolimus therapy. J Clin Pharmacol 2002;42:798-805. DOI |
19 | Knight SR. Intrapatient variability in tacrolimus exposure-a useful tool for clinical practice? Transpl Int 2016;29:1155-7 DOI |
20 | Rodrigo E, Segundo DS, Fernandez-Fresnedo G, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation 2016;100:2479-85. DOI |